Key Points
-
Migraine — an episodic headache — is caused by the activation of the so-called trigeminovascular system (TGVS): trigeminal afferents lead to the activation of structures that are involved in the transmission and perception of pain, and to the release of vasoactive peptides (presumably causing neurogenic inflammation).
-
The two main open issues in the neurobiology of migraine headache are the primary cause of activation of the TGVS and the mechanism of pain generation after activation of the TGVS.
-
Two ideas have dominated the field regarding the primary cause of TGVS activation: cortical spreading depression (a slowly moving wave of cortical depolarization) and the existence of a brainstem generator (dysfunctional brainstem nuclei involved in antinociception as a primary cause of migraine). In any case, alterations in cortical excitability seem to be related to migraine attacks.
-
Regarding the pain mechanisms in migraine, two main ideas have been considered: neurogenic inflammation of the meninges, and sensitization of the trigeminal nerve and nucleus.
-
Migraine has a strong genetic component. So far, the only two genes that have been identified, both causing a rare form of migraine, are CACNA1A (which encodes a subunit of the voltage-gated Ca2+ channel CaV2.1) and ATP1A2 (which encodes a subunit of the Na+/K+ ATPase).
-
Migraine-linked mutations in CACNA1A alter the biophysical properties and density of CaV2.1, but how this phenotype translates into the neurological condition remains unclear. Similarly, the mutations in ATP1A2 lead to a loss of ATPase function, but it remains to be established how this phenotype leads to the onset of migraine.
-
The identification of the most probable primary cause of TGVS activation, the increased understanding of the pain mechanisms in migraine, and the discovery of migraine-linked mutations provide us with new targets for the development of anti-migraine compounds. This is an area of paramount importance owing to the prevalence of the condition and to the fact that currently available drugs are not always effective.
Abstract
Migraine — an episodic headache — affects more than 10% of the general population. Despite recent progress, drug therapy for preventing and treating migraine remains unsatisfactory for many patients. One problem that slows the development of new therapeutic approaches is our limited understanding of migraine neurobiology. Activation of the trigeminovascular system is a central step in the development of migraine. However, two main issues remain incompletely understood: the primary cause of migraine, leading to activation of the trigeminovascular system, and the mechanisms of pain generation after its activation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The de novo CACNA1A pathogenic variant Y1384C associated with hemiplegic migraine, early onset cerebellar atrophy and developmental delay leads to a loss of Cav2.1 channel function
Molecular Brain Open Access 08 February 2021
-
A CACNA1A variant associated with trigeminal neuralgia alters the gating of Cav2.1 channels
Molecular Brain Open Access 07 January 2021
-
Response inhibition alterations in migraine: evidence from event-related potentials and evoked oscillations
The Journal of Headache and Pain Open Access 02 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Wessman, M. et al. A susceptibility locus for migraine with aura, on chromosome 4q24. Am. J. Hum. Genet. 70, 652–662 (2002).
Moskowitz, M. A. & Macfarlane, R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metab. Rev. 5, 159–177 (1993).
May, A. & Goadsby, P. J. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J. Cereb. Blood Flow Metab. 19, 115–127 (1999).
Goadsby, P. J., Lipton, R. B. & Ferrari, M. D. Migraine — current understanding and treatment. N. Engl. J. Med. 346, 257–270 (2002).
Knight, Y. E. & Goadsby, P. J. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 106, 793–800 (2001).
Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).
Sarchielli, P., Alberti, A., Codini, M., Floridi, A. & Gallai, V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20, 907–918 (2000).
Goadsby, P. J. & Edvinsson, L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33, 48–56 (1993).
Olesen, J., Larsen, B. & Lauritzen, M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann. Neurol. 9, 344–352 (1981).
Limmroth, V. et al. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J. Neurol. Sci. 138, 60–65 (1996).
Kruuse, C., Thomsen, L. L., Birk, S. & Olesen, J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126, 241–247 (2003). This observation lent important support to findings from imaging studies and clinical trials with 5-HT 1F -selective triptans, indicating that initial vasodilation of extracerebral arteries is not required to trigger migraine attacks. It also indicated that vasodilation might not be as important for the induction of migraine attacks by other vasodilators as previously thought.
Leao, A. A. P. Spreading depression of activity in the cerebral cortex. J. Neurophysiol. 7, 359–390 (1944).
Lauritzen, M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 117, 199–210 (1994).
Mayevsky, A. et al. Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. Brain Res. 740, 268–274 (1996).
Strong, A. J. et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33, 2738–2743 (2002).
Yokota, C. et al. Unique profile of spreading depression in a primate model. J. Cereb. Blood Flow Metab. 22, 835–842 (2002).
Hadjikhani, N. et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA 98, 4687–4692 (2001). The most thorough investigation of changes in neuronal activity during migraine aura. Signal changes showed a number of characteristics that were consistent with CSD during migriane aura in humans.
Welch, K. M., Cao, Y., Aurora, S., Wiggins, G. & Vikingstad, E. M. MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology 51, 1465–1469 (1998).
Bowyer, S. M., Aurora, K. S., Moran, J. E., Tepley, N. & Welch, K. M. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol. 50, 582–587 (2001). This study provided the important demonstration that CSD-typical changes of direct current neuromagnetic field measurements in animals also occur during spontaneous and visually triggered migraine auras in migraineurs.
Bowyer, S. M. et al. Analysis of MEG signals of spreading cortical depression with propagation constrained to a rectangular cortical strip. II. Gyrencephalic swine model. Brain Res. 843, 79–86 (1999).
Somjen, G. G. Mechanisms of spreading depression and hypoxic spreading depression- like depolarization. Physiol. Rev. 81, 1065–1096 (2001).
Strassman, A. M., Raymond, S. A. & Burstein, R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384, 560–564 (1996).
Wei, E. P., Moskowitz, M. A., Boccalini, P. & Kontos, H. A. Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ. Res. 70, 1313–1319 (1992).
Bolay, H. et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Med. 8, 136–142 (2002). This study convincingly showed that electrically and pinprick-induced CSD can activate the trigeminovascular afferents and can induce the pathophysiological features of migraine attacks.
Ebersberger, A., Schaible, H. G., Averbeck, B. & Richter, F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann. Neurol. 49, 7–13 (2001).
Lambert, G. A., Michalicek, J., Storer, R. J. & Zagami, A. S. Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. Cephalalgia 19, 631–638 (1999).
Woods, R. P., Iacoboni, M. & Mazziotta, J. C. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N. Engl. J. Med. 331, 1689–1692 (1994).
Bednarczyk, E. M., Remler, B., Weikart, C., Nelson, A. D. & Reed, R. C. Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology 50, 1736–1740 (1998).
Sanchez del Rio, M. et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19, 701–707 (1999).
Cao, Y., Aurora, S. K., Nagesh, V., Patel, S. C. & Welch, K. M. Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 59, 72–78 (2002). Using BOLD-fMRI, this study showed activation of the red nucleus and substantia nigra during visually triggered migraine and hyperaemia in the occipital cortex, independently of whether the headache was preceded by visual symptoms.
Goadsby, P. J. Migraine, aura, and cortical spreading depression: why are we still talking about it? Ann. Neurol. 49, 4–6 (2001).
Raskin, N. H., Hosobuchi, Y. & Lamb, S. Headache may arise from perturbation of brain. Headache 27, 416–420 (1987).
Weiller, C. et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1, 658–660 (1995). First report showing increased blood flow in the brainstem during spontaneous migraine attacks. This finding promoted the hypothesis of a brainstem generator of migraine.
Bahra, A., Matharu, M. S., Buchel, C., Frackowiak, R. S. & Goadsby, P. J. Brainstem activation specific to migraine headache. Lancet 357, 1016–1017 (2001).
Lima, D. & Almeida, A. The medullary dorsal reticular nucleus as a pronociceptive centre of the pain control system. Prog. Neurobiol. 66, 81–108 (2002).
Millan, M. J. Descending control of pain. Prog. Neurobiol. 66, 355–474 (2002).
May, A., Bahra, A., Buchel, C., Frackowiak, R. S. & Goadsby, P. J. Hypothalamic activation in cluster headache attacks. Lancet 352, 275–278 (1998).
May, A. et al. Experimental cranial pain elicited by capsaicin: a PET study. Pain 74, 61–66 (1998).
Strassman, A., Mason, P., Moskowitz, M. & Maciewicz, R. Response of brainstem trigeminal neurons to electrical stimulation of the dura. Brain Res. 379, 242–250 (1986).
Chronicle, E. P. & Mulleners, W. M. Visual system dysfunction in migraine: a review of clinical and psychophysical findings. Cephalalgia 16, 525–535 (1996).
Brighina, F., Piazza, A., Daniele, O. & Fierro, B. Modulation of visual cortical excitability in migraine with aura: effects of 1 Hz repetitive transcranial magnetic stimulation. Exp. Brain. Res. 145, 177–181 (2002).
Battelli, L., Black, K. R. & Wray, S. H. Transcranial magnetic stimulation of visual area V5 in migraine. Neurology 58, 1066–1069 (2002).
Giffin, N. J. & Kaube, H. The electrophysiology of migraine. Curr. Opin. Neurol. 15, 303–309 (2002).
Afra, J., Mascia, A., Gerard, P., Maertens de Noordhout, A. & Schoenen, J. Interictal cortical excitability in migraine: a study using transcranial magnetic stimulation of motor and visual cortices. Ann. Neuro. 44, 209–215 (1998).
Werhahn, K. J. et al. Motor cortex excitability in patients with migraine with aura and hemiplegic migraine. Cephalalgia 20, 45–50 (2000).
Bocker, K. B., Timsit-Berthier, M., Schoenen, J. & Brunia, C. H. Contingent negative variation in migraine. Headache 30, 604–609 (1990).
Kropp, P., Siniatchkin, M., Stephani, U. & Gerber, W. D. Migraine — evidence for a disturbance of cerebral maturation in man? Neurosci. Lett. 276, 181–184 (1999).
Besken, E., Pothmann, R. & Sartory, G. Contingent negative variation in childhood migraine. Cephalalgia 13, 42–43 (1993).
Bender, S. et al. Lack of age-dependent development of the contingent negative variation (CNV) in migraine children? Cephalalgia 22, 132–136 (2002).
Kropp, P. & Gerber, W. D. Is increased amplitude of contingent negative variation in migraine due to cortical hyperactivity or to reduced habituation? Cephalalgia 13, 37–41 (1993).
Wang, W. & Schoenen, J. Interictal potentiation of passive 'oddball' auditory event-related potentials in migraine. Cephalalgia 18, 261–265 (1998).
Ozkul, Y. & Uckardes, A. Median nerve somatosensory evoked potentials in migraine. Eur. J. Neurol. 9, 227–232 (2002).
Wilson, D. A. Habituation of odor responses in the rat anterior piriform cortex. J. Neurophysiol. 79, 1425–1440 (1998).
Wang, W., Wang, Y. H., Fu, X. M., Sun, Z. M. & Schoenen, J. Auditory evoked potentials and multiple personality measures in migraine and post-traumatic headaches. Pain 79, 235–242 (1999).
Hegerl, U., Gallinat, J. & Juckel, G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J. Affect. Disord. 62, 93–100 (2001).
Evers, S., Quibeldey, F., Grotemeyer, K. H., Suhr, B. & Husstedt, I. W. Dynamic changes of cognitive habituation and serotonin metabolism during the migraine interval. Cephalalgia 19, 485–491 (1999).
Siniatchkin, M., Kropp, P., Gerber, W. D. & Stephani, U. Migraine in childhood — are periodically occurring migraine attacks related to dynamic changes of cortical information processing? Neurosci. Lett. 279, 1–4 (2000).
Siniatchkin, M., Gerber, W. D., Kropp, P. & Vein, A. How the brain anticipates an attack: a study of neurophysiological periodicity in migraine. Funct. Neurol. 14, 69–77 (1999).
Bohotin, V. et al. Effects of repetitive transcranial magnetic stimulation on visual evoked potentials in migraine. Brain 125, 912–922 (2002).
Gu, Q. Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity. Neuroscience 111, 815–835 (2002).
Gartside, S. E. et al. Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 98, 295–300 (2000).
Ferrari, M. D. & Saxena, P. R. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 13, 151–165 (1993).
Ferrari, M. D., Odink, J., Bos, K. D., Malessy, M. J. & Bruyn, G. W. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 40, 1582–1586 (1990).
Welch, K. M. & Ramadan, N. M. Mitochondria, magnesium and migraine. J. Neurol. Sci. 134, 9–14 (1995).
Boska, M. D., Welch, K. M., Barker, P. B., Nelson, J. A. & Schultz, L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 58, 1227–1233 (2002).
Parsons, A. A. Recent advances in mechanisms of spreading depression. Curr. Opin. Neurol. 11, 227–231 (1998).
Arakawa, S., Nakamura, S., Kawashima, N., Nishiike, S. & Fujii, Y. Antidromic burst activity of locus coeruleus neurons during cortical spreading depression. Neuroscience 78, 1147–1158 (1997).
Kruger, H., Luhmann, H. J. & Heinemann, U. Repetitive spreading depression causes selective suppression of GABAergic function. Neuroreport 7, 2733–2736 (1996).
Goadsby, P. J. The pharmacology of headache. Prog. Neurobiol. 62, 509–525 (2000).
May, A. et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 121, 1231–1237 (1998).
Cumberbatch, M. J., Williamson, D. J., Mason, G. S., Hill, R. G. & Hargreaves, R. J. Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br. J. Pharmacol. 126, 1478–1486 (1999).
Lassen, L. H. et al. CGRP may play a causative role in migraine. Cephalalgia 22, 54–61 (2002).
Williamson, D. J., Hill, R. G., Shepheard, S. L. & Hargreaves, R. J. The anti-migraine 5-HT1B/1D agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br. J. Pharmacol. 133, 1029–1034 (2001).
Goldstein, D. J. et al. Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358, 1230–1234 (2001). Although further development of LY334370 was halted, this clinical trial provided good evidence for the efficacy of 5-HT 1F -selective antagonists as anti-migraine drugs, and supported the concept that anti-migraine efficacy does not require vasoconstrictory actions.
Shepheard, S. et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19, 851–858 (1999).
Kaube, H. et al. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 58, 1234–1238 (2002).
Burstein, R., Yarnitsky, D., Goor-Aryeh, I., Ransil, B. J. & Bajwa, Z. H. An association between migraine and cutaneous allodynia. Ann. Neurol. 47, 614–624 (2000).
Burstein, R., Yamamura, H., Malick, A. & Strassman, A. M. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J. Neurophysiol. 79, 964–982 (1998). References 22, 77 and 78 are key papers for our understanding of pain sensitization in migraine. The data provide evidence for sensitization of TNC neurons in humans during migraine attacks and in rats after chemical stimulation of the dura, and are consistent with the idea that initiation, but not maintenance, of central sensitization depends on incoming impulses from nocieptors.
Burstein, R., Cutrer, M. F. & Yarnitsky, D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123, 1703–1709 (2000).
Woolf, C. J. & Salter, M. W. Neuronal plasticity: increasing the gain in pain. Science 288, 1765–1769 (2000).
Sandrini, G. et al. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine. Neurosci. Lett. 317, 135–138 (2002).
Grosser, K. et al. Olfactory and trigeminal event-related potentials in migraine. Cephalalgia 20, 621–631 (2000).
Thomsen, L. L. & Olesen, J. Nitric oxide in primary headaches. Curr. Opin. Neurol. 14, 315–321 (2001).
Akerman, S., Williamson, D. J., Kaube, H. & Goadsby, P. J. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol. 137, 62–68 (2002).
Pardutz, A., Krizbai, I., Multon, S., Vecsei, L. & Schoenen, J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 11, 3071–3075 (2000).
Hoskin, K. L., Bulmer, D. C. & Goadsby, P. J. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci. Lett. 266, 173–176 (1999).
Lambert, G. A., Donaldson, C., Boers, P. M. & Zagami, A. S. Activation of trigeminovascular neurons by glyceryl trinitrate. Brain Res. 887, 203–210 (2000).
Jones, M. G. et al. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia 21, 643–655 (2001).
Thomsen, L. L. et al. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain 125, 1379–1391 (2002).
Ducros, A. et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N. Engl. J. Med. 345, 17–24 (2001). The authors identified several new FHM mutations and correlated the mutations with clinical parameters. The data strongly indicated that pure FHM and FHM with cerebellar signs are associated with distinct mutations in CACNA1A.
Ophoff, R. A. et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the calcium channel gene CACNL1A4. Cell 87, 543–552 (1996). First report showing that missense mutations in CACNA1A cause FHM. Mutations leading to more pronounced structural abnormalities (such as truncations) were identified as the cause of episodic ataxia type 2, an autosomal dominant disease.
Kors, E. E., van den Maagdenberg, A. M., Plomp, J. J., Frants, R. R. & Ferrari, M. D. Calcium channel mutations and migraine. Curr. Opin. Neurol. 15, 311–316 (2002).
Pietrobon, D. Calcium channels and channelopathies of the central nervous system. Mol. Neurobiol. 25, 31–50 (2002).
De Fusco, M. et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit gene is responsible for familial hemiplegic migraine type 2. Nature Genet. 33, 192–196 (2003). This paper reported the long-awaited identification of the gene in chromosome 1q23 linked to FHM. It was identified as ATP1A2 , encoding the Na+/K+ ATPase α 2 -subunit. Functional studies indicate a loss of function of a single allele as the relevant pathophysiological mechanism.
Terwindt, G. M. et al. Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology 56, 1028–1032 (2001).
Nyholt, D. R., Lea, R. A., Goadsby, P. J., Brimage, P. J. & Griffiths, L. R. Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology 50, 1428–1432 (1998).
Jones, K. W. et al. Migraine with aura susceptibility locus on chromosome 19p13 is distinct from the familial hemiplegic migraine locus. Genomics 78, 150–154 (2001).
Westenbroek, R. E. et al. Immunochemical identification and subcellular distribution of the α1A subunits of brain calcium channels. J. Neurosci. 15, 6403–6418 (1995).
Mintz, I. M., Sabatini, B. L. & Regehr, W. G. Calcium control of transmitter release at a cerebellar synapse. Neuron 15, 675–688 (1995).
Wu, L. G., Westenbroek, R. E., Borst, J. G., Catterall, W. A. & Sakmann, B. Calcium channel types with distinct presynaptic localization couple differentially to transmitter release in single calyx-type synapses. J. Neurosci. 19, 726–736 (1999).
Qian, J. & Noebels, J. L. Presynaptic Ca2+ channels and neurotransmitter release at the terminal of a mouse cortical neuron. J. Neurosci. 21, 3721–3728 (2001).
Bayliss, D. A., Li, Y. -W. & Talley, E. M. Effects of serotonin on caudal raphe neurons: inhibition of N- and P/Q-type calcium channels and the afterhyperpolarization. J. Neurophysiol. 1362–1374 (1997).
Pineda, J. C., Waters, R. S. & Foehring, R. C. Specificity in the interaction of HVA Ca2+ channel types with Ca2+- dependent AHPs and firing behavior in neocortical pyramidal neurons. J. Neurophysiol. 79, 2522–2534 (1998).
Mori, Y. et al. Reduced voltage sensitivity of activation of P/Q-type Ca2+ channels is associated with the ataxic mouse mutation Rolling Nagoya (tgrol). J. Neurosci. 20, 5654–5662 (2000).
Sutton, K. G., McRory, J. E., Guthrie, H., Murphy, T. H. & Snutch, T. P. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A. Nature 401, 800–804 (1999).
Volsen, S. G. et al. The expression of neuronal voltage-dependent calcium channels in human cerebellum. Brain Res. Mol. Brain Res. 34, 271–282 (1995).
Mintz, I. M., Adams, M. E. & Bean, B. P. P-type calcium channels in rat central and peripheral neurons. Neuron 9, 85–95 (1992).
Randall, A. & Tsien, R. W. Pharmacological dissection of multiple types of calcium channels currents in rat cerebellar granule neurons. J. Neurosci. 15, 2995–3012 (1995).
Tottene, A., Moretti, A. & Pietrobon, D. Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. J. Neurosci. 16, 6353–6363 (1996).
Iwasaki, S., Momiyama, A., Uchitel, O. D. & Takahashi, T. Developmental changes in calcium channel types mediating central synaptic transmission. J. Neurosci. 20, 59–65 (2000).
Stephens, G. J., Morris, N. P., Fyffe, R. E. & Robertson, B. The Cav2.1/α1A (P/Q-type) voltage-dependent calcium channel mediates inhibitory neurotransmission onto mouse cerebellar Purkinje cells. Eur. J. Neurosci. 13, 1902–1912 (2001).
Matsushita, K. et al. Bidirectional alterations in cerebellar synaptic transmission of tottering and rolling Ca2+ channel mutant mice. J. Neurosci. 22, 4388–4398 (2002).
Eilers, J., Plant, T. & Konnerth, A. Localized calcium signalling and neuronal integration in cerebellar Purkinje neurones. Cell Calcium 20, 215–226 (1996).
Fletcher, C. F. et al. Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J. 15, 1288–1290 (2001).
Jun, K. et al. Ablation of P/Q-type Ca2+ channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the α1A-subunit. Proc. Natl Acad. Sci. USA 96, 15245–15250 (1999).
Zhuchenko, O. et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nature Genet. 15, 62–69 (1997).
Timmermann, D. B., Westenbroek, R. E., Schousboe, A. & Catterall, W. A. Distribution of high-voltage-activated calcium channels in cultured γ-aminobutyric acidergic neurons from mouse cerebral cortex. J. Neurosci. Res. 67, 48–61 (2002).
Lorenzon, N. M. & Foehring, R. C. Characterization of pharmacologically identified voltage-gated calcium channel currents in acutely isolated rat neocortical neurons. I. Adult neurons. J. Neurophysiol. 73, 1430–1442 (1995).
Koester, H. J. & Sakmann, B. Calcium dynamics associated with action potentials in single nerve terminals of pyramidal cells in layer 2/3 of the young rat neocortex. J. Physiol. (Lond.) 529, 625–646 (2000).
Turner, T. J., Adams, M. E. & Dunlap, K. Calcium channels coupled to glutamate release identified by ω-Aga-IVA. Science 258, 310–313 (1992).
Wakamori, M. et al. Single tottering mutations responsible for the neuropathic phenotype of the P-type calcium channel. J. Biol. Chem. 273, 34857–34867 (1998).
Dove, L. S., Abbott, L. C. & Griffith, W. H. Whole-cell and single-channel analysis of P-type calcium currents in cerebellar Purkinje cells of leaner mutant mice. J. Neurosci. 18, 7687–7699 (1998).
Ayata, C., Shimizu-Sasamata, M., Lo, E. H., Noebels, J. L. & Moskowitz, M. A. Impaired neurotransmitter release and elevated threshold for cortical spreading depression in mice with mutations in the α1A subunit of P/Q type calcium channels. Neuroscience 95, 639–645 (2000). This study exploited naturally occuring Ca v 2.1α 1 mutations in leaner mouse mutants to show that P/Q-type channels contribute to the initiation and propagation of CSD in the neocortex. A defect in KCl-induced transmitter release and a striking elevation of CSD threshold in both types of mice were identified.
Richter, F., Ebersberger, A. & Schaible, H. G. Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depression. Neurosci. Lett. 334, 123–126 (2002).
Hillmann, D. et al. Localization of P-type calcium channels in the central nervous system. Proc. Natl Acad. Sci. USA 88, 7076–7080 (1991).
Craig, P. J. et al. Distribution of the voltage-dependent calcium channel α1A subunit throughout the mature rat brain and its relationship to neurotransmitter pathways. J. Comp. Neurol. 397, 251–267 (1998).
Kim, C. J., Rhee, J. S. & Akaike, N. Modulation of high-voltage activated Ca2+ channels in the rat periaqueductal gray neurons by μ-type opioid agonist. J. Neurophysiol. 77, 1418–1424 (1997).
Connor, M. & Christie, M. J. Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J. Physiol. (Lond.) 509, 47–58 (1998).
Penington, N. J. & Fox, A. P. Toxin-insensitive Ca current in dorsal raphe neurons. J. Neurosci. 15, 5719–2726 (1995).
Chieng, B. & Bekkers, J. M. GABAB, opioid and α2 receptor inhibition of calcium channels in acutely-dissociated locus coeruleus neurones. Br. J. Pharmacol. 127, 1533–1538 (1999).
Ishibashi, H., Rhee, J. S. & Akaike, N. Regional difference of high voltage-activated Ca2+ channels in rat CNS neurones. Neuroreport 6, 1621–1624 (1995).
Knight, Y. E., Bartsch, T., Kaube, H. & Goadsby, P. J. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J. Neurosci. 22, RC213 (2002). The first study to investigate P/Q-type channel function on descending antinociceptive activity. By recording electrical responses of TNC neurons to electrical, dural stimulation, it was shown that the agatoxin IVA-induced P/Q-channel block in the ventrolateral PAG facilitated responses of second-order neurons. This indicated a role of P/Q-type channels in the PAG for trigeminal antinociception.
Borgland, S. L., Connor, M. & Christie, M. J. Nociceptin inhibits calcium channel currents in a subpopulation of small nociceptive trigeminal ganglion neurons in mouse. J. Physiol. (Lond.) 536, 35–47 (2001).
Hong, K. W., Kim, C. D., Rhim, B. Y. & Lee, W. S. Effect of ω-conotoxin GVIA and ω-agatoxin IVA on the capsaicin-sensitive calcitonin gene-related peptide release and autoregulatory vasodilation in rat pial arteries. J. Cereb. Blood Flow Metab. 19, 53–60 (1999).
Asakura, K. et al. α-Eudesmol, a P/Q-type Ca2+ channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 873, 94–101 (2000).
Westenbroek, R. E., Hoskins, L. & Catterall, W. A. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J. Neurosci. 18, 6319–6330 (1998).
Vanegas, H. & Schaible, H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 85, 9–18 (2000).
Takahashi, T. & Momiyama, A. Different types of calcium channels mediate central synaptic transmission. Nature 366, 156–158 (1993).
Ogasawara, M., Kurihara, T., Hu, Q. & Tanabe, T. Characterization of acute somatosensory pain transmission in P/Q-type Ca2+ channel mutant mice, leaner. FEBS Lett. 508, 181–6 (2001).
Kors, E. E. et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann. Neurol. 49, 753–760 (2001).
Kraus, R. L., Sinnegger, M. J., Glossmann, H., Hering, S. & Striessnig, J. Familial hemiplegic migraine mutations change α1A calcium channel kinetics. J. Biol. Chem. 273, 5586–5590 (1998).
Hans, M. et al. Functional consequences of mutations in the human α1A calcium channel subunit linked to familial hemiplegic migraine. J. Neurosci. 19, 1610–1619 (1999).
Kraus, R. L. et al. Three new familial hemiplegic migraine mutants affect P/Q-type Ca2+ channel kinetics. J. Biol. Chem. 275, 9239–9243 (2000).
Tottene, A. et al. Familial hemiplegic migraine mutations increase Ca2+ influx through single human Cav2.1 channels and decrease maximal Cav2.1 current density in neurons. Proc. Natl Acad. Sci. USA 99, 13284–13289 (2002). This paper reported the expression of FHM mutant Ca v 2.1α 1 constructs in Ca v 2.1α 1 deficient neurons, and disclosed two functional effects that are common to all analysed FHM mutations: increase of single-channel Ca2+ influx over a broad range of negative voltages and decrease of channel density. These findings provide a unifying hypothesis for the pathophysiology of FHM.
Meinrenken, C. J., Borst, J. G. & Sakmann, B. Calcium secretion coupling at calyx of Held governed by nonuniform channel-vesicle topography. J. Neurosci. 22, 1648–1667 (2002).
Borst, J. G. & Sakmann, B. Calcium current during a single action potential in a large presynaptic terminal of the rat brainstem. J. Physiol. (Lond.) 506, 143–157 (1998).
Juhaszova, M. & Blaustein, M. P. Na+ pump low and high ouabain affinity α subunit isoforms are differently distributed in cells. Proc. Natl Acad. Sci. USA 94, 1800–1805 (1997).
Snow, V., Weiss, K., Wall, E. M. & Mottur-Pilson, C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137, 840–849 (2002).
Goadsby, P. J., Hoskin, K. L., Storer, R. J., Edvinsson, L. & Connor, H. E. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125, 1392–1401 (2002).
Penn, R. D. & Paice, J. A. Adverse effects associated with the intrathecal administration of ziconotide. Pain 85, 291–296 (2000).
Sang, C. N. et al. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 89, 1060–1067 (1998).
Gilron, I. et al. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol. Ther. 68, 320–327 (2000).
Ramadan, N. M. Acute treatments: future developments. Curr. Med. Res. Opin. 17, Suppl. S81–86 (2001).
Le Grand, B., Panissie, A., Perez, M., Pauwels, P. J. & John, G. W. Zolmitriptan stimulates a Ca2+-dependent K+ current in C6 glioma cells stably expressing recombinant human 5-HT1B receptors. Eur. J. Pharmacol. 397, 297–302 (2000).
John, G. W. et al. F-11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J. Pharmacol. Exp. Ther. 290, 83–95 (1999).
Diamond, S., Freitag, F., Phillips, S. B., Bernstein, J. E. & Saper, J. R. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia 20, 597–602 (2000).
Mulleners, W. M., Chronicle, E. P., Vredeveld, J. W. & Koehler, P. J. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. Eur. J. Neurol. 9, 35–40 (2002).
Kaube, H., Herzog, J., Kaufer, T., Dichgans, M. & Diener, H. C. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55, 139–141 (2000).
Bradley, D. P. et al. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and tonabersat. Exp. Neurol. 172, 342–353 (2001).
Acknowledgements
Our work is funded by the Austrian Science Fund, Telethon-Italia, the Italian Ministry of University and Research, and the European Community.
Author information
Authors and Affiliations
Corresponding author
Glossary
- POLYGENIC
-
A characteristic controlled by different genes, each of which has only a small role in the phenotype.
- EXTRAVASATION
-
The exit of fluid from a blood vessel.
- SCOTOMA
-
An area of lost vision that is surrounded by an area of less depressed or normal vision.
- MAGNETOENCEPHALOGRAPHY
-
A non-invasive technique that allows the detection of the changing magnetic fields that are associated with brain activity. As the magnetic fields of the brain are very weak, extremely sensitive magnetic detectors known as superconducting quantum interference devices, which work at very low, superconducting temperatures (−269 °C), are used to pick up the signal.
- FOS
-
An immediate early gene that is rapidly turned on when many types of neuron increase their activity. It can therefore be used to identify responsive neurons.
- PERFUSION-WEIGHTED IMAGING
-
Imaging technique in which the magnetic resonance signal is intrinsically sensitive to the presence and rate of blood perfusion. It commonly involves the intravenous injection of a bolus of a contrast agent, and the subsequent imaging of the changes in signal intensity as the contrast agent first passes through the brain.
- TRANSCRANIAL MAGNETIC STIMULATION
-
A technique that is used to induce a transient interruption of normal activity in a relatively restricted area of the brain. It is based on the generation of a strong magnetic field near the area of interest, which, if changed rapidly enough, will induce an electric field that is sufficient to stimulate neurons.
- PHOSPHENES
-
Luminous perceptions that are elicited by excitation of the retina by means other than light itself, as when the eyeballs are pressed through closed lids.
- INTERICTAL
-
Refers to events that occur between attacks or paroxysms.
- EVENT-RELATED POTENTIALS
-
Electrical potentials that are generated in the brain as a consequence of the synchronized activation of neuronal networks by external stimuli. These evoked potentials are recorded at the scalp and consist of precisely timed sequences of waves or 'components'.
- CONTINGENT NEGATIVE VARIATION
-
A small electroencephalographic potential that is often recorded as subjects perform expectation- or attention-dependent tasks. It is also known as the expectation or E wave.
- P300 POTENTIAL
-
A positive waveform in the electroencephalogram that occurs about 300 ms after the onset of a stimulus, and is related to the attentional and working memory demands of a task.
- PAIRED-PULSE DEPRESSION
-
When two depolarizing stimuli are delivered in close succession to a group of axons, their average response to the second one is sometimes smaller than to the first. This form of short-term plasticity is more common at inhibitory than at excitatory synapses.
- ALLODYNIA
-
The perception of a stimulus as painful when previously the same stimulus was reported to be non-painful.
- ATAXIA
-
Lack of movement coordination that is commonly associated with cerebellar damage.
- NYSTAGMUS
-
An involuntary, rapid and rhythmic movement of the eyeball.
- MISSENSE MUTATIONS
-
Mutations that result in the substitution of an amino acid in a protein.
- LINKAGE ANALYSIS
-
An analysis of the frequency of co-inheritance of a pair of genetic markers to obtain an index of their physical proximity on a chromosome.
- SIB-PAIRS ANALYSIS
-
A means to establish whether affected siblings have the same allele at a particular locus.
- SNARE PROTEINS
-
A family of membrane-tethered coiled-coil proteins that are required for membrane fusion in exocytosis (such as during neurotransmitter release) and other membrane transport events. When trans-SNARE complexes are formed between vesicle SNAREs and target-membrane SNAREs, they pull the two membranes close together, presumably causing them to fuse.
- DYSTONIA
-
The occurrence of dyskinetic movements due to alterations of muscle tone.
- SPIKE-FREQUENCY ADAPTATION
-
A decrease in the rate of action potentials fired by a neuron under prolonged depolarization.
- LEANER MICE
-
Mice with mutations in Cacna1a. They are characterized by marked cerebellar atrophy that is accompanied by ataxia, wobbly gait and dyskinesia.
- PENETRANCE
-
The probability that an individual with a particular genotype will manifest a given phenotype. Complete penetrance corresponds to the situation in which every individual with the same specific genotype manifests the phenotype in question.
- ACTIVE ZONE
-
A portion of the presynaptic membrane that faces the postsynaptic density across the synaptic cleft. It constitutes the site of synaptic vesicle clustering, docking and transmitter release.
- KNOCK-IN
-
The insertion of a mutant gene at the exact site in the genome where the corresponding wild-type gene is located. This approach is used to ensure that the effect of the mutant gene is not affected by the activity of the endogenous locus.
Rights and permissions
About this article
Cite this article
Pietrobon, D., Striessnig, J. Neurobiology of migraine. Nat Rev Neurosci 4, 386–398 (2003). https://doi.org/10.1038/nrn1102
Issue Date:
DOI: https://doi.org/10.1038/nrn1102
This article is cited by
-
The de novo CACNA1A pathogenic variant Y1384C associated with hemiplegic migraine, early onset cerebellar atrophy and developmental delay leads to a loss of Cav2.1 channel function
Molecular Brain (2021)
-
A CACNA1A variant associated with trigeminal neuralgia alters the gating of Cav2.1 channels
Molecular Brain (2021)
-
Genetic variants in migraine: a field synopsis and systematic re-analysis of meta-analyses
The Journal of Headache and Pain (2020)
-
Response inhibition alterations in migraine: evidence from event-related potentials and evoked oscillations
The Journal of Headache and Pain (2020)
-
The role of the immune system and the biomarker CD3 + CD4 + CD45RA−CD62L− in the pathophysiology of migraine
Scientific Reports (2020)